All In Biotech

Drug Trial Radar · NCT05563220

Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer

A Phase 1b/2, Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer

Last checked: Nov 19, 2026Latest source record: Jun 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

435

Planned (sponsor's estimate)

Start

Jan 24, 2023

Primary completion

Dec 27, 2026

Study completion Dec 28, 2028

Sponsor

Lead sponsor
Stemline Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Oct 3, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, Phase 1b/2 trial in participants with estrogen receptor positive/human epidermal growth factor receptor 2 negative (ER+/HER2-) advanced/metastatic breast cancer. The phase 1b part of the trial will determine the recommended Phase 2 dose (RP2D) of elacestrant when administered in combination with alpelisib, everolimus, palbociclib, capivasertib, and ribociclib. The Phase 2 part of the trial will evaluate the efficacy and safety of the various combinations.

Conditions

  • Breast Cancer
  • Metastatic Breast Cancer

Interventions

  • ElacestrantDrug

    Elacestrant 86 mg, 172 mg, 258 mg or 345 mg once daily in cycles of 28 days

  • AlpelisibDrug

    Alpelisib 150 mg or 250 mg once daily in cycles of 28 days

  • EverolimusDrug

    Everolimus 5 mg, 7.5 mg, or 10 mg once daily in cycles of 28 days

  • RibociclibDrug

    Ribociclib 400 mg or 600 mg once daily for 21 days followed by 7 days off in cycles of 28 days

  • PalbociclibDrug

    Palbociclib 100 mg or 125 mg once daily for 21 days followed by 7 days off in cycles of 28 days

  • CapivasertibDrug

    Capivasertib 200 mg or 320 mg or 400 mg twice daily for 4 days on, 3 days off in cycles of 28 days

  • AbemaciclibDrug

    Abemaciclib 100 mg or 150 mg twice daily in cycles of 28 consecutive days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with DLTs Observed During the First CycleTime frame: 28 days
  2. Progression-free SurvivalTime frame: 6 months

Locations

83 sites in 13 countries. Site status is shown where the registry gives one.

  • Dothan Hematology and Oncology

    Dothan, Alabama

  • Mayo Clinic - Arizona

    Phoenix, Arizona

  • Highlands Oncology Group

    Springdale, Arkansas

  • City of Hope National Medical Center

    Duarte, California

  • OPN Healthcare (Los Alamitos Location)

    Los Alamitos, California

  • Cedars Sinai

    Los Angeles, California

  • UCLA UCLA Hem/Onc - Clinical Research Unit

    Los Angeles, California

  • UCSF Helen Diller Family Comprehensive Cancer Center

    San Francisco, California

  • TOI Clinical Research

    Whittier, California

  • Rocky Mountain Cancer Centers

    Lone Tree, Colorado

  • George Washington Cancer Center

    Washington D.C., District of Columbia

  • Advent Health (Florida Hospital) - Altamonte Springs

    Altamonte Springs, Florida

  • Mayo Clinic - Jacksonville

    Jacksonville, Florida

  • Northwestern Feinberg Scholl of Medicine Prentice Women's Hospital

    Chicago, Illinois

  • MD Alliance for Multispecialty Research, LLC

    Merriam, Kansas

  • Johns Hopkins School of Medicine

    Baltimore, Maryland

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • Barbara Ann Karmanos Cancer Institute

    Detroit, Michigan

  • Mayo Clinic - Rochester

    Rochester, Minnesota

  • Washington University School of Medicine in St. Louis

    St Louis, Missouri

  • Astera Cancer Care

    East Brunswick, New Jersey

  • Summit Medical Group

    Florham Park, New Jersey

  • Cooperman Barnabas Medical Center

    New Brunswick, New Jersey

  • NYU Langone Health

    New York, New York

  • W&IH of RI Breast Health Center of Women and Infants Hospital of Rhode Island

    Providence, Rhode Island

  • Sarah Cannon Research Institute / Tennessee Oncology

    Nashville, Tennessee

  • Texas Oncology - Baylor Charles A. Sammons Cancer Center

    Dallas, Texas

  • MD Anderson Cancer Center Texas

    Houston, Texas

  • UT Health San Antonio

    San Antonio, Texas

  • Virginia Cancer Specialists

    Fairfax, Virginia

  • Virginia Oncology Associates

    Norfolk, Virginia

  • Cancer Care Northwest

    Spokane Valley, Washington

  • Northwest Medical Specialties (Nwms) - Puyallup - Medical Oncology (Rainier Hematology-Oncology)/Exigent Research Network; LLC

    Tacoma, Washington

  • University of WI - Carbone Cancer Center (Phase II only)

    Madison, Wisconsin

  • Centro Medico Austral

    Buenos Aires, Argentina

  • Cemaic - Centro De Especialidades Medicas Ambulatorias E Investigacion Clinica

    Córdoba, Argentina

  • Centro Oncologico Riojano Integral (Cori)

    La Rioja, Argentina

  • Macquarie University

    Sydney, Australia

  • Institut Jules Bordet

    Anderlecht, Belgium

Showing 40 of 83 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.